Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

VOCALE LBD: Online Peer Support for Caregivers of People With Lewy Body Dementia (VOCALE LBD)

7 novembre 2026 mis à jour par: Oleg Zaslavsky, University of Washington

Reducing Depression in Family Caregivers of Persons Living With Lewy Body Dementia Through Tailored Asynchronous Online Intervention.

This study tests whether a tailored, fully asynchronous online group intervention (VOCALE LBD) reduces depression in family caregivers of people with Lewy Body Dementia (LBD), compared to standard educational materials. LBD is the second most common form of degenerative dementia and causes distinct challenges, including visual hallucinations, REM sleep disorder, and severe motor symptoms, that are not addressed by generic caregiver interventions. Depression rates in LBD caregivers reach 40-50%, double the rate seen in Alzheimer's disease caregivers, yet no rigorous digital interventions exist specifically for this population. VOCALE LBD is a text-based, low-bandwidth platform (Discourse) that brings groups of 10-15 caregivers together in an 8-week moderated online community. Weekly topics address LBD-specific challenges (sleep problems, hallucinations, self-care) and problem-solving skills using the ADAPT method. A pilot study (n=54) showed strong effects on depressive symptoms (Cohen's d=0.54 at 1-month follow-up), near-perfect engagement, and high participant satisfaction. This RCT (N=220) will test efficacy, examine mechanisms of action (self-efficacy and problem-solving), and explore analytics approaches for pragmatic monitoring, laying groundwork for future implementation in clinics and community organizations.

Aperçu de l'étude

Description détaillée

Over 1.4 million people in the U.S. are diagnosed with Lewy Body Dementia (LBD). Up to 80% receive care from family members, yet family caregivers of people with LBD experience depression at rates (40-50%) double those of Alzheimer's disease caregivers. LBD's distinct features - visual hallucinations, REM sleep behavior disorder, cognitive fluctuations, and Parkinsonian motor symptoms - create caregiving demands not addressed by existing dementia caregiver interventions. Current pharmacological treatments for LBD are largely experimental, leaving families to manage severe behavioral and motor symptoms without adequate support. INTERVENTION: VOCALE LBD (Virtual Online Communities for Aging Life Experiences - Lewy Body Dementia) is a fully asynchronous, text-based online group intervention delivered via the Discourse platform. The 8-week program includes icebreaker activities followed by LBD-specific weekly topics (self-care, sleep problems, hallucinations and delusions) and problem-solving training using the ADAPT method (Adopting a positive attitude, Defining the problem, brainstorming Alternatives, Predicting consequences, Trying the solution). Groups of 10-15 caregivers are moderated by a licensed nurse or social worker (RN/LCSW), who logs in daily and facilitates discussions. The platform requires no video conferencing and is accessible via any internet-connected device. Loaner devices and digital literacy training are provided for participants who need them. STUDY DESIGN: Two-arm, randomized controlled trial. Participants are randomized 1:1 to (a) VOCALE LBD or (b) Standard of Care (SOC: NIA psychoeducational materials, LBDA resource list, problem-solving handouts). Assessment time points: baseline, post-intervention (week 8), and 6-month follow-up. Exit interviews are conducted at the end of the intervention. AIMS: Aim 1 tests whether VOCALE LBD reduces depressive symptoms (CES-D) compared to SOC at week 8, with sustained effect at 6 months. Aim 2 examines mechanisms - whether self-efficacy and problem-solving mediate outcomes (2a quantitative mediation; 2b qualitative analysis). Aim 3 explores pragmatic monitoring using user engagement analytics, natural language processing, and LLM-assisted moderator support tools. RECRUITMENT: Nationwide recruitment through the Lewy Body Dementia Association (LBDA) via eblasts, social media, support groups, and print materials. Additional outreach via Alzheimer.gov and national LBD caregiver web resources.

Type d'étude

Interventionnel

Inscription (Estimé)

220

Phase

  • N'est pas applicable

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

  • Nom: Oleg Zaslavsky, PhD, RN
  • Numéro de téléphone: (206) 849-3301
  • E-mail: zaslav@uw.edu

Sauvegarde des contacts de l'étude

  • Nom: Aimy Paulsen, MPH
  • Numéro de téléphone: (253) 693-8329
  • E-mail: vocale-lbd@uw.edu

Lieux d'étude

    • Washington
      • Seattle, Washington, États-Unis, 98195
        • Recrutement
        • University of Washington
        • Contact:
          • Oleg Zaslavsky, PhD, RN
          • Numéro de téléphone: (206) 849-3301
          • E-mail: zaslav@uw.edu
        • Contact:
        • Chercheur principal:
          • Oleg Zaslavsky, PhD, RN

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans et plus (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria:

  • Current family member or informal (unpaid) caregiver of a person with a confirmed diagnosis of Lewy Body Dementia (LBD) or LBD mixed pathology
  • Experiences depressive symptoms as defined by a score of 5 or higher on the Patient Health Questionnaire-9 (PHQ-9)
  • Able to read, write, and speak English
  • Has access to a device (computer, tablet, or smartphone) that can connect to the internet and be used for videoconferencing or phone calls, OR is interested in using a loaner device
  • Has an active email address OR is willing to create and use an email address prior to enrollment

Exclusion Criteria:

  • Active suicidal ideation as indicated by endorsement of PHQ-9 Item 9 (thoughts that you would be better off dead, or thoughts of hurting yourself)
  • Paid or professional caregiver (must be unpaid family/informal caregiver)
  • Unable to read, write, or speak English

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Seul

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: VOCALE LBD

Participants in this arm receive the VOCALE LBD intervention: an 8-week, fully asynchronous, text-based online group program delivered via the Discourse platform. Groups of 10-15 participants are facilitated by trained moderators who log in daily. Weekly discussion topics address LBD-specific caregiving challenges (sleep problems, hallucinations and delusions) and problem-solving skills training using the ADAPT method. Participants are asked to make a minimum of three posts each week (e.g., adding a post, replying to two other users).

The 8-week VOCALE LBD intervention is delivered asynchronously via the Discourse online platform. The weekly curriculum includes: Pre-intervention (Icebreakers, Self-introductions); Week 1 (Sleep Problems); Week 2 (Hallucinations and Delusions); Week 3 (ADAPT - Positive Attitude); Week 4 (ADAPT - Define the Problem); Week 5 (ADAPT - Alternative Solutions); Week 6 (ADAPT - Plan); Week 7 (ADAPT - Try); Week 8 (Reflection and Wrap Up).

Autres noms:
  • VOCALE LBD
  • Virtual Online Community
  • Asynchronous Online Group Intervention
Comparateur actif: Standard of Care

NIA and LBDA psychoeducational materials on LBD and caregiving; LBDA resource list; problem-solving principles handout. Materials delivered via email.

NIA and LBDA psychoeducational materials on LBD and caregiving; LBDA resource list; problem-solving principles handout. Materials delivered via email or mail per participant preference.

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Center for Epidemiologic Studies Depression Scale (CES-D)
Délai: Baseline (pre-randomization), Post-intervention (Week 8), 6-month follow-up

The Center for Epidemiologic Studies Depression Scale (CES-D) is a 20-item self-report questionnaire that evaluates the frequency of depressive symptoms experienced in the past week (including depressed mood, feelings of guilt/worthlessness, helplessness, and physical symptoms). Total scores range from 0 to 60. Higher scores indicate greater severity of depressive symptoms (worse outcome).

Baseline (pre-randomization), Post-intervention (Week 8), 6-month follow-up

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Short Zarit Caregiver Burden Interview (ZBI-12)
Délai: Baseline, Week 8, 6-month follow-up

The Short Zarit Caregiver Burden Interview (ZBI-12) is a 12-item self-report instrument that measures personal strain and role strain associated with caregiving. Total scores range from 0 to 48. Higher scores indicate greater caregiver burden (worse outcome).

Baseline, Week 8, 6-month follow-up
UCLA Loneliness Scale (3-Item Short Form)
Délai: Baseline, Week 8, 6-month follow-up

The UCLA Loneliness Scale (3-Item Short Form) is a 3-item self-report survey assessing subjective feelings of loneliness and social isolation. Total scores range from 3 to 9. Higher scores indicate greater loneliness and social isolation (worse outcome).

Baseline, Week 8, 6-month follow-up
Perceived Stress Scale (PSS-10)
Délai: Baseline, Week 8, 6-month follow-up

The Perceived Stress Scale (PSS-10) is a 10-item instrument measuring an individual's perception of stress and feelings of unpredictability, uncontrollability, and overload during the past month. Total scores range from 0 to 40. Higher scores indicate greater perceived stress (worse outcome).

Baseline, Week 8, 6-month follow-up
Medical Outcomes Study Social Support Survey (MOS-SSS)
Délai: Baseline, Week 5 (mid-intervention), Week 8, 6-month follow-up

The Medical Outcomes Study Social Support Survey (MOS-SSS) is a 19-item questionnaire evaluating multiple dimensions of social support (emotional/informational, tangible, affectionate, and positive social interaction). Raw total scores range from 19 to 95 (which can be transformed to an overall index score of 0 to 100). Higher scores indicate greater social support (better outcome).

Baseline, Week 5 (mid-intervention), Week 8, 6-month follow-up

Autres mesures de résultats

Mesure des résultats
Description de la mesure
Délai
Social Problem-Solving Inventory-Revised (SPSI-R Short Form)
Délai: Baseline, Week 5, Week 8, 6-month follow-up

The Social Problem-Solving Inventory-Revised (SPSI-R:S) is a 25-item self-report instrument assessing cognitive and behavioral problem-solving orientations and skills across five subscales (Positive Problem Orientation, Negative Problem Orientation, Rational Problem Solving, Impulsivity/Carelessness Style, and Avoidance Style). Standardized total scores range from 0 to 20. Higher total scores indicate better social problem-solving skills (better outcome). Used as mechanistic measure.

Baseline, Week 5, Week 8, 6-month follow-up
General Self-Efficacy Scale (GSE)
Délai: Baseline, Week 5, Week 8, 6-month follow-up

The General Self-Efficacy Scale (GSE) is a 10-item self-report questionnaire assessing optimistic self-beliefs and confidence in coping with daily difficulties and novel situations. Total scores range from 10 to 40. Higher scores indicate greater general self-efficacy (better outcome).

Baseline, Week 5, Week 8, 6-month follow-up
Caregiver Self-Efficacy Scale (CSES-8)
Délai: Baseline, Week 5, Week 8, 6-month follow-up

The Caregiver Self-Efficacy Scale is an 8-item self-report questionnaire measuring caregiver confidence in managing caregiving demands, obtaining respite, and handling challenging behaviors. Total scores range from 0 to 100 (percent confidence). Higher scores indicate greater caregiver self-efficacy (better outcome).

Baseline, Week 5, Week 8, 6-month follow-up
User Engagement Scale (UES)
Délai: Week 8

The User Engagement Scale (UES) is a 31-item self-report survey characterizing the depth and quality of participant interactions with the online discussion platform across four subdomains (focused attention, perceived usability, aesthetic appeal, and reward). Mean item scores range from 1 to 5. Higher scores indicate greater platform engagement (better outcome).

Week 8
Benefits of Participating Scale
Délai: Week 8, 6-month follow-up

The Benefits of Participating Scale is a 4-item questionnaire evaluating perceived personal benefit and satisfaction with program participation (rated on a 3-point scale: 1 = Not at all, 2 = Some, 3 = A great deal). Total scores range from 4 to 12. Higher scores indicate greater perceived benefit and study satisfaction (better outcome).

Week 8, 6-month follow-up

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Les enquêteurs

  • Chercheur principal: Oleg Zaslavsky, PhD, RN, University of Washington, School of Nursing

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Estimé)

1 décembre 2026

Achèvement primaire (Estimé)

30 novembre 2029

Achèvement de l'étude (Estimé)

30 novembre 2030

Dates d'inscription aux études

Première soumission

3 juin 2026

Première soumission répondant aux critères de contrôle qualité

3 juin 2026

Première publication (Réel)

9 juin 2026

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

12 novembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

7 novembre 2026

Dernière vérification

1 novembre 2026

Plus d'information

Termes liés à cette étude

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

OUI

Description du régime IPD

De-identified individual participant data that underlie the results reported in publications (text, tables, figures, appendices) will be shared. Data will be made available 9 months following publication of the primary study results. Data will be deposited in an NIH-designated repository (e.g., NIMH Data Archive or ICPSR). Requests for data should include a data analysis plan and be submitted to the PI.

Délai de partage IPD

Beginning 9 months after publication of primary outcome results; available for 5 years.

Critères d'accès au partage IPD

Researchers who provide a methodologically sound data analysis plan. Proposals should be directed to zaslav@uw.edu. To gain access, data requestors will need to sign a data access agreement.

Type d'informations de prise en charge du partage d'IPD

  • PROTOCOLE D'ÉTUDE
  • SÈVE
  • CIF

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner